Fulcrum Therapeutics Inc [FULC] stock is trading at $3.57, down -5.31%. An important factor to consider is whether the stock is rising or falling in short-term value. The FULC shares have gain 11.56% over the last week, with a monthly amount drifted -59.15%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Fulcrum Therapeutics Inc [NASDAQ: FULC] stock has seen the most recent analyst activity on September 13, 2024, when H.C. Wainwright downgraded its rating to a Neutral and also revised its price target to $4 from $17. Previously, Stifel downgraded its rating to Hold on September 12, 2024. On September 12, 2024, downgrade downgraded it’s rating to Sector Perform and revised its price target to $4 on the stock. Leerink Partners downgraded its rating to a Market Perform but stick to its price target of $4 on September 12, 2024. Cantor Fitzgerald downgraded its rating to a Neutral. BofA Securities downgraded its rating to Underperform for this stock on September 12, 2024, and downed its price target to $2. In a note dated September 09, 2024, BofA Securities upgraded an Neutral rating on this stock and boosted its target price from $5 to $10.
Fulcrum Therapeutics Inc [FULC] stock has fluctuated between $2.87 and $13.70 over the past year. Currently, Wall Street analysts expect the stock to reach $9.86 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $3.57 at the most recent close of the market. An investor can expect a potential return of 176.19% based on the average FULC price forecast.
Analyzing the FULC fundamentals
Fulcrum Therapeutics Inc [NASDAQ:FULC] reported sales of 81.63M for the trailing twelve months, which represents a growth of 8990.91%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.4%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.08 and Total Capital is -0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.48 points at the first support level, and at 3.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.74, and for the 2nd resistance point, it is at 3.92.
Ratios To Look Out For
For context, Fulcrum Therapeutics Inc’s Current Ratio is 22.07. On the other hand, the Quick Ratio is 22.07, and the Cash Ratio is 6.83. Considering the valuation of this stock, the price to sales ratio is 2.73, the price to book ratio is 0.81.
Transactions by insiders
Recent insider trading involved Tourangeau Greg, Principal Accounting Officer, that happened on May 07 ’24 when 236.0 shares were sold. Vice President, Finance, Tourangeau Greg completed a deal on Mar 08 ’24 to sell 4884.0 shares. Meanwhile, Sapir Alex bought 43360.0 shares on Mar 04 ’24.
